(Q37150732)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

review article

1 reference

title

Prevention of type 1 diabetes: the time has come (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

4

Kevan C Herold

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

3

Jay S Skyler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

2

Jay Sosenko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

29 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Endocrinology and Metabolism

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

334-343

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

Type I diabetes mellitus. A chronic autoimmune disease

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

Factors associated with early remission of type I diabetes in children treated with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Genetics of autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Type 1 diabetes: new perspectives on disease pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Beta-cell autoantibodies in infants and toddlers without IDDM relatives: diabetes autoimmunity study in the young (DAISY)

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Pancreatic islet-cell antibody as a marker for asymptomatic and latent diabetes and prediabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Precision of the islet-cell antibody assay depends on the pancreas

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

The rise and fall of insulin secretion in type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Role of insulin resistance in predicting progression to type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Effects of insulin in relatives of patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Preventive and Therapeutic Effects of Large-Dose Nicotinamide Injections on Diabetes Associated with Insulitis: An Observation in Nonobese Diabetic (NOD) Mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Insulin prophylaxis in individuals at high risk of type I diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Nicotinamide--biological actions and therapeutic potential in diabetes prevention. IDIG Workshop, Copenhagen, Denmark, 4-5 December 1992.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Follow-up report on the diagnosis of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Recovery from diabetes in mice by beta cell regeneration

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Exendin-4 modulates diabetes onset in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Insulin resistance is a risk factor for progression to type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

The cumulative incidence of childhood diabetes mellitus in Sweden unaffected by BCG-vaccination.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Bacille Calmette-Guérin vaccination and incidence of IDDM in Montreal, Canada

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Elimination of dietary gluten does not reduce titers of type 1 diabetes-associated autoantibodies in high-risk subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Intranasally administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0832

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0832

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18446141%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference